What are the recommended antibiotics for treating Acinetobacter bacteremia in an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recommended Antibiotics for Acinetobacter Bacteremia

For carbapenem-susceptible Acinetobacter baumannii bacteremia, use carbapenems (imipenem 0.5-1g every 6 hours or meropenem 2g every 8 hours); for carbapenem-resistant strains, use colistin with a loading dose of 6-9 million IU followed by 4.5 million IU every 12 hours, or polymyxin B 1.5-3 mg/kg/day with a 2-2.5 mg/kg loading dose. 1

Treatment Algorithm Based on Resistance Pattern

For Carbapenem-Susceptible A. baumannii

  • First-line: Carbapenems are the drugs of choice in areas with low carbapenem resistance rates 1
    • Imipenem: 0.5-1g every 6 hours (extended infusion not possible due to drug instability)
    • Meropenem: 2g every 8 hours (high doses associated with seizure risk) 1

For Carbapenem-Resistant A. baumannii (CRAB)

Primary options:

  1. Colistin (Polymyxin E) - Reserve for strains resistant to all beta-lactams, fluoroquinolones, and tigecycline 1

    • Loading dose: 6-9 million IU (essential - plasma concentrations remain suboptimal for 2-3 days without loading) 1
    • Maintenance: 4.5 million IU every 12 hours in critically ill patients with creatinine clearance >50 mL/min
    • Adjust maintenance dose based on renal function 1
    • Critical caveat: Suboptimal serum concentrations are common with standard dosing, associated with higher mortality 1

  2. Polymyxin B - May be preferable due to lower nephrotoxicity 1

    • Loading dose: 2-2.5 mg/kg
    • Maintenance: 1.5-3 mg/kg/day in 2 divided doses
    • Advantage: No dose adjustment needed for continuous renal replacement therapy; lower renal failure incidence than colistin 1

  3. Sulbactam - Consider when MIC ≤4 mg/L and strain is colistin-susceptible 1

    • Dose: 9-12g/day in 3 divided doses
    • 4-hour infusion recommended for optimal pharmacokinetics
    • May be preferable to colistin based on better safety profile (lower nephrotoxicity and mortality in some studies) 1

Critical Warnings About Tigecycline for Bacteremia

Tigecycline should NOT be used for Acinetobacter bacteremia with standard dosing. 1

  • Standard dose (100mg loading, then 50mg twice daily) achieves maximum serum concentration of only 0.87 mg/L - insufficient for bloodstream infections 1
  • Clinical series confirm poor outcomes in A. baumannii bacteremia treated with tigecycline 1
  • If used at all, only consider high-dose regimen (200mg loading, then 100mg every 12 hours) for secondary bacteremia from approved indications (complicated intra-abdominal or skin infections), and always in combination with another active agent 1

Combination Therapy Considerations

The evidence for combination therapy is mixed: The 2022 ESCMID guidelines note that large RCTs (AIDA and OVERCOME trials) showed no mortality benefit for colistin-carbapenem combinations over colistin monotherapy in CRAB infections 2. However, combination therapy is commonly used in clinical practice, particularly for severe infections.

Colistin-rifampin combination: A powered RCT of 209 patients showed no advantage over colistin monotherapy for 30-day mortality 2

Renal Replacement Therapy Dosing

  • Colistin on CRRT: At least 9 million IU/day 1
  • Colistin on intermittent hemodialysis: 2 million IU every 12 hours with normal loading dose; perform dialysis toward end of dosing interval 1
  • Polymyxin B on CRRT: No dose adjustment necessary 1

Common Pitfalls to Avoid

  1. Failing to use loading doses - Both colistin and polymyxin B require loading doses to achieve therapeutic levels rapidly 1
  2. Using tigecycline monotherapy at standard doses for bacteremia - This is associated with treatment failure 1
  3. Not adjusting colistin for renal function - Maintenance doses must be individualized based on creatinine clearance 1
  4. Assuming carbapenem combinations work for CRAB - High-quality RCT evidence shows no benefit when A. baumannii MICs to carbapenems are >16 mg/L 2

References

Related Questions

When Acinetobacter baumannii is isolated from blood, should an infectious disease consultation be obtained and is meropenem 1 g every 8 hours an appropriate initial therapy?
What empiric antimicrobial coverage is recommended for Acinetobacter infections?
What is the recommended antibiotic regimen for Acinetobacter radiodurans infection, including options for carbapenem‑sensitive and carbapenem‑resistant isolates?
When Acinetobacter baumannii is isolated, what agents is it intrinsically resistant to, and should an infectious disease consultation be requested or empiric therapy initiated?
What are the treatment strategies for an infant (1–12 months) with extensively drug‑resistant Acinetobacter baumannii that is only susceptible to aminoglycosides?
Which is the preferred fluid for correcting hyponatremia, lactated Ringer's solution or 0.9% normal saline?
What conditions does human papillomavirus (HPV) cause in men?
What is the appropriate ICU management plan for a mechanically ventilated patient with a tracheostomy?
What are the indications, recommended dosing, and appropriate combination partners for ampicillin‑sulbactam (Unasyn) when treating Acinetobacter infections?
What is the recommended evaluation and management for delayed primary tooth eruption in a child older than 12 months (girls) or 14 months (boys) with fewer than three teeth?
Is central nervous system prophylaxis required for patients with diffuse large B‑cell lymphoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.